Business Description
Caribou Biosciences is a clinical-stage biotechnology company founded in 2011 and based in Berkeley, California. The company has developed a proprietary gene-editing platform that uses a hybrid RNA-DNA approach to modify donor-derived immune cells, allowing treatments to be manufactured in advance rather than tailored to each individual patient. Caribou is currently running two early-stage clinical trials testing these off-the-shelf cell therapies in patients with certain blood cancers, including aggressive lymphoma and multiple myeloma, who have not responded to prior treatment.
